PARTNER PROFILE

Institute for Health Data Science, Lanzhou University | China

Accelerating the translation of evidence to practice in China.

 

Overview

Learn more about about the Institute for Health Data Science team and how PEERSS supports their work.

Team members

Meet the experts that make up the PEERSS team in China.

Research

See the most recent research and resources from the Institute for Health Data Science.

Connect

Connect directly with the China team.

Partner team overview

Lanzhou University Institute of Health Data Science logo

The Institute of Health Data Science at Lanzhou University was established in January 2020 and aims to accelerate the translation of evidence to practice in China.

Under the PEERSS partnership, the Institute of Health Data Science has worked to make evidence more accessible and decisions more collaborative in China.

With PEERSS funding and support, the Institute has worked to:

Disseminate social and health-related Chinese COVID-19 literature and share the Chinese experience with other countries and organizations.

Establish a COVID-19 Chinese evidence sharing platform which is accessible to researchers and decision-makers around the world.

Provide Chinese evidence and relevant policies to support other PEERSS partner teams.

Gain the trust of key decision-makers and stakeholders in the evidence-informed policymaking space.

Moving forward, partners from China will continue to promote evidence-informed policymaking by:

Conducting methodological research on the evidence-based social science ecosystem.

Holding stakeholder dialogues and workshops with key actors to promote international collaboration.

Conducting a rapid synthesis and developing a policy brief that is informed by that synthesis.

Meet the experts from China.

Role
Team Lead
Areas of Expertise
Clinical practice guidelines; Reporting guidelines
Country
China
Role
Researcher
Areas of Expertise
Statistics; Public management
Country
China
Role
Coordinator, Researcher
Areas of Expertise
Evidence-based social science
Country
China
Role
Researcher
Areas of Expertise
Evidence brief for policy; Health policy
Country
China
Role
Researcher
Areas of Expertise
Health Policy, Evidence-informed policymaking; Health system guidance
Country
China

Publications, policy briefs and other resources from the Institute for Health Data Science

PEERSS Site Icon

Consort 2021

The reporting quality of randomised controlled trials is still being perfected. However, reporting guidelines such as CONSORT and PRISMA are not well disseminated and implemented in China.
Language

English

Year Published

2010

Type of Resource

Guidelines

Managing conflicts of interest in practice guidelines panels

Practice guidelines are an important innovation in patient care. According to the 2011 Institute of Medicine (IOM) definition, practice guidelines are “statements that include recommendations, intended to optimize patient care, that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options.”1 In the United States, guideline programs began in the early 1980s. As guidelines have been used for decisions about insurance coverage and standards for measuring quality of care, they have become increasingly influential, and conflict of interest (COI) in developing guidelines has become an important concern.
Language

English

Year Published

2017

Type of Resource

Guidelines

Clinical practice guidelines in China

Yaolong Chen and coworkers analyse the situation and challenges for clinical practice guidelines in China and provide recommendations for their development and implementation.
Language

English

Year Published

2018

Type of Resource

Guidelines

Clinical practice guidelines for COVID-19

In 2011, the United States-based Institute of Medicine (IOM) defined clinical practice guidelines as “statements that include recommendations, intended to optimize patient care, that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options”.1 In the past two decades, the number of global guidelines, whether in the field of Western medicine, traditional Chinese medicine, or integrated Chinese and Western medicine, has been growing rapidly, and its methodology has become gradually advanced.2, 3, 4, 5 Around the development, implementation, and research of the clinical practice guidelines, professional organizations (such as the Guidelines International Network, GIN6) and working groups (such as the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group,7 Appraisal of Guidelines for Research and Evaluation (AGREE) working group,8 Reporting Items for Practice Guidelines in Healthcare (RIGHT) working group9) have been established. At the same time, the guideline methodologists have naturally become a new profession.10, 11
Language

English

Year Published

2020

Type of Resource

Guidelines

Clinical Practice Guidelines Registry: Toward Reducing Duplication, Improving Collaboration, and Increasing Transparency

Clinical trials, systematic reviews (SRs), and trustworthy clinical practice guidelines (CPGs) are central to evidence ecosystems and evidence-based health care. Efficient and transparent measures should be in place to share information about any planned work. Prospective registration provides researchers with an open platform to post protocols and record the progress of studies. Prior registration of clinical trials and SRs has brought an opportunity to improve the transparency in methods and objectives, reduce unnecessary duplication and potential biases, and provide a more reliable evidence basis for CPGs (1–3).
Language

English

Year Published

2021

Type of Resource

Guidelines

Rapid advice guidelines for management of children with COVID-19

An infectious disease, caused by a novel coronavirus, emerged in Wuhan City, China. The disease was later named coronavirus disease 2019 (COVID-19) and the virus causing it was named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rapid spread of COVID-19 worldwide has brought great challenges to local and global public health security and health systems. On March 12, 2020, the World Health Organization (WHO) declared the coronavirus outbreak a global pandemic and raised the risk of a global SARS-CoV-2 outbreak to “very high” (1-6).
Language

English

Year Published

2020

Type of Resource

Guidelines

Have a question about the research from China?

Use the contact form below to submit a message to the PEERSS team or reach out via email.

china@peerss.org

PEERSS PARTNERS

Explore the World of Evidence

tooltip text
\
tooltip text

Brazil

\
tooltip text

Cameroon

\
tooltip text

China

\
tooltip text

Ethiopia

\
tooltip text

Nigeria

\
tooltip text

Burkina Faso

\
tooltip text

Trinidad and Tobago

\
tooltip text

United Kingdom

\
tooltip text

Chile

\
tooltip text

Colombia

\
tooltip text

Lebanon

\
tooltip text

South Africa

\
tooltip text

Uganda

en_USEnglish